See analyst estimates and all valuation multiples for Biopharmaceuticals
Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
---|---|---|---|
$693B | 12.4x | 29.4x | |
$454B | 5.0x | 13.5x | |
$431B | 7.3x | 15.9x | |
$285B | 3.7x | 9.4x | |
$273B | 4.7x | 13.6x | |
$269B | 4.9x | 11.9x | |
$260B | 5.4x | 11.0x | |
$235B | 3.6x | 8.2x | |
$202B | 5.8x | 10.9x | |
$188B | 3.0x | 7.6x | |
$159B | 5.5x | 11.2x | |
$133B | 2.8x | 9.3x | |
$131B | 2.5x | 8.4x | |
$98.3B | 2.3x | 6.8x | |
$95.7B | 8.2x | 24.7x | |
$75.4B | 4.8x | 14.5x | |
$74.7B | 2.4x | 9.3x | |
$74.0B | 7.8x | 18.1x | |
$70.3B | 1.3x | 6.2x | |
$64.9B | 8.0x | 15.8x | |
$63.7B | 2.6x | 9.1x | |
$54.0B | 6.0x | 20.8x | |
$53.4B | 12.1x | 42.1x | |
$42.2B | 3.2x | 15.2x | |
$40.8B | 6.6x | 23.0x | |
$35.3B | 2.1x | 7.3x | |
$31.1B | 2.8x | 13.4x | |
$28.9B | 10.1x | 30.7x | |
$26.4B | 1.6x | 7.0x | |
$26.1B | 1.8x | 6.1x | |
$23.8B | 1.8x | 8.9x | |
$23.4B | 12.2x | 32.7x | |
$23.3B | 2.4x | 7.2x | |
$22.5B | 2.3x | 6.6x | |
$21.9B | 7.5x | 8.0x | |
$19.1B | 12.4x | 198.7x | |
$18.1B | 2.1x | 8.5x | |
$18.1B | 39.0x | 130.9x | |
$17.1B | 41.2x | -6126.0x | |
$16.6B | 3.8x | 15.0x | |
$15.6B | 109.8x | 208.2x | |
$15.1B | 5.1x | 13.6x | |
$14.2B | 10.2x | 31.1x | |
$13.4B | 4.2x | 16.5x | |
$13.2B | 5.0x | 20.8x | |
$12.9B | 47.7x | -334.1x | |
$12.9B | 2.2x | 14.2x | |
$12.7B | 3.6x | 9.7x | |
$12.5B | 3.1x | 11.6x | |
$12.4B | 8.2x | 32.2x | |
$12.4B | 2.2x | 15.5x | |
$11.8B | 3.1x | 12.0x | |
$11.7B | 0.3x | 5.3x | |
$11.7B | 4.1x | 11.2x | |
$11.4B | 5.9x | 18.5x | |
$11.0B | 3.5x | 8.9x | |
$10.7B | 3.9x | 13.5x | |
$10.7B | 1.7x | 5.5x | |
$10.5B | 2.5x | 7.0x | |
$10.5B | 3.3x | 8.2x | |
$10.3B | 1.7x | 13.2x | |
$10.2B | 3.8x | 15.6x | |
$9.5B | 7.8x | 11.9x | |
$9.0B | 30.2x | -362.5x | |
$8.4B | 1.6x | 12.8x | |
$8.4B | n/a | n/a | |
$8.0B | 4.0x | 7.0x | |
$7.8B | 10.5x | 34.6x | |
$7.7B | n/a | n/a | |
$7.6B | 18.7x | 26.4x | |
$7.4B | 2.3x | 9.9x | |
$7.3B | 9.6x | 35.6x | |
$7.1B | 4.6x | 23.3x | |
$6.9B | 3.8x | 18.0x | |
$6.8B | 1.8x | 8.9x | |
$6.8B | n/a | n/a | |
$6.8B | 2.1x | 7.8x | |
$6.7B | 19.6x | -117.8x | |
$6.5B | 1.6x | 8.3x | |
$6.3B | 4.0x | 21.1x | |
$6.2B | 2.7x | 9.9x | |
$6.1B | 4.0x | 54.3x | |
$6.0B | 522.9x | -30.3x | |
$5.9B | 5.0x | 16.3x | |
$5.9B | 7.2x | 25.1x | |
$5.7B | 17.3x | -53.0x | |
$5.7B | 10.6x | 34.8x | |
$5.5B | 6.8x | 30.5x | |
$5.5B | 1.9x | 8.3x | |
$5.3B | 5.8x | 14.1x | |
$5.2B | 2.0x | 5.3x | |
$5.2B | 1.6x | 7.0x | |
$5.2B | n/a | n/a | |
$5.2B | 2.8x | 11.2x | |
$5.0B | 11.4x | 36.0x | |
$4.8B | n/a | n/a | |
$4.8B | 11.0x | 38.6x | |
$4.6B | 9.6x | 31.2x | |
$4.3B | 12.4x | 87.0x | |
$4.3B | 1.7x | 7.0x | |
$4.2B | 6.3x | n/a | |
$4.2B | 3.0x | 10.8x | |
$4.1B | 8.7x | 19.9x | |
$4.0B | 6.1x | 15.8x | |
$3.9B | 38.5x | -43.8x | |
$3.8B | 2.6x | 9.9x | |
$3.8B | 4.7x | n/a | |
$3.6B | 6.0x | 17.7x | |
$3.6B | 35.1x | -12532.4x | |
$3.6B | 4.2x | 15.5x | |
$3.5B | 2.1x | 10.3x | |
$3.4B | 18.2x | -73.3x | |
$3.4B | 5.0x | 16.4x | |
$3.3B | 1.6x | 10.6x | |
$3.2B | 41.3x | 268.3x | |
$3.2B | 2.3x | 8.5x | |
$3.2B | n/a | n/a | |
$3.1B | n/a | n/a | |
$3.0B | 772.3x | -9.0x | |
$2.9B | 2.4x | 11.6x | |
$2.9B | 2.6x | 12.4x | |
$2.9B | 7.5x | 22.1x | |
$2.9B | 16.2x | -40.5x | |
$2.8B | n/a | n/a | |
$2.8B | 3.5x | 18.0x | |
$2.7B | 27.4x | -45.6x | |
$2.6B | 4.4x | 14.5x | |
$2.5B | 3.2x | 17.3x | |
$2.5B | 6.7x | 18.9x | |
$2.5B | 19.9x | 34.1x | |
$2.5B | 6.6x | 15.2x | |
$2.4B | 3.2x | 12.3x | |
$2.3B | 5.8x | 17.3x | |
$2.2B | n/a | -15.4x | |
$2.2B | 3.9x | 43.5x | |
$2.1B | 6.3x | -31.0x | |
$2.1B | 7.0x | 13.5x | |
$2.1B | 3.0x | 11.9x | |
$2.0B | 40.2x | n/a | |
$2.0B | 14.1x | n/a | |
$2.0B | 13.5x | 32.7x | |
$2.0B | n/a | n/a | |
$2.0B | 53.8x | n/a | |
$1.9B | 3.0x | 7.1x | |
$1.9B | 4.4x | n/a | |
$1.9B | 4.4x | 17.0x | |
$1.8B | 2.5x | 6.7x | |
$1.8B | n/a | n/a | |
$1.8B | 2.5x | 4.2x | |
$1.8B | 6.2x | -26.7x | |
$1.8B | 0.8x | 4.7x | |
$1.7B | 4.7x | -14.2x | |
$1.6B | 6.4x | 26.4x | |
$1.6B | n/a | -6.9x | |
$1.6B | 7.1x | 25.0x | |
$1.6B | n/a | n/a | |
$1.5B | 2.4x | 10.4x | |
$1.5B | 4.1x | -106.4x | |
$1.5B | 5.8x | 46.4x | |
$1.5B | n/a | -7.8x | |
$1.4B | 69.9x | -16.4x | |
$1.4B | 20.1x | -8.5x | |
$1.4B | 1.4x | 5.8x | |
$1.4B | n/a | n/a | |
$1.4B | 5.3x | n/a | |
$1.3B | 5.6x | 71.3x | |
$1.3B | 2.2x | -76.0x | |
$1.3B | 3.1x | 15.4x | |
$1.3B | 16.4x | 28.6x | |
$1.3B | 1.9x | -9.1x | |
$1.2B | n/a | -6.9x | |
$1.2B | 0.5x | 4.8x | |
$1.2B | 3.3x | n/a | |
$1.2B | 6.4x | 21.8x | |
$1.2B | 2.5x | 14.5x | |
$1.1B | 10.1x | 40.5x | |
$1.1B | n/a | n/a | |
$1.1B | 10.3x | 288.9x | |
$1.1B | 5.2x | 13.6x | |
$1.0B | 9.9x | 42.4x | |
$1.0B | n/a | n/a | |
$1.0B | n/a | n/a | |
$984M | 3.5x | 4.3x | |
$972M | n/a | n/a | |
$967M | 2.9x | 64.9x | |
$944M | n/a | n/a | |
$939M | 7.8x | -3.2x | |
$933M | 7.2x | -5.1x | |
$882M | n/a | -10.8x | |
$881M | 103.5x | -12.4x | |
$876M | n/a | n/a | |
$876M | 2.8x | 40.8x | |
$874M | n/a | -2.4x | |
$861M | 7.4x | -12.6x | |
$856M | 13162.3x | -4.0x | |
$848M | 1.0x | 4.7x | |
$838M | 6.2x | -31.6x | |
$819M | 7.3x | -7.4x | |
$818M | 1.3x | 6.4x | |
$777M | n/a | -3.6x | |
$746M | 3.7x | n/a | |
$745M | n/a | n/a | |
$724M | n/a | n/a | |
$720M | 2.4x | 6.4x | |
$716M | 151839.7x | -6.1x | |
$699M | 58.1x | -5.8x | |
$695M | n/a | -4.8x | |
$694M | n/a | n/a | |
$694M | 32.3x | -216.4x | |
$693M | 6.6x | 24.3x | |
$691M | n/a | n/a | |
$690M | n/a | n/a | |
$684M | n/a | -3.5x | |
$667M | 208.3x | -2.6x | |
$664M | 2.5x | 9.9x | |
$662M | 1.9x | 23.1x | |
$660M | 1.5x | 7.2x | |
$658M | 692.3x | -7.2x | |
$613M | 11.4x | n/a | |
$607M | 52.3x | n/a | |
$602M | n/a | -4.5x | |
$594M | 563.7x | -30.4x | |
$583M | 3.2x | 16.2x | |
$544M | n/a | -4.3x | |
$543M | 143.6x | n/a | |
$517M | 5.1x | 15.1x | |
$512M | 198.7x | -3.9x | |
$501M | n/a | n/a | |
$500M | n/a | n/a | |
$475M | 6.9x | -22.7x | |
$457M | 1.4x | 5.5x | |
$453M | 1.2x | 9.1x | |
$453M | 26.3x | -12.1x | |
$450M | 1.6x | 11.2x | |
$450M | 9.7x | 78.8x | |
$449M | 19.1x | n/a | |
$448M | n/a | n/a | |
$439M | 2.8x | 12.5x | |
$429M | n/a | n/a | |
$422M | 3.5x | 381.5x | |
$412M | 49.7x | -2.2x | |
$408M | n/a | n/a | |
$406M | 3.5x | 7.7x | |
$386M | 6.8x | -4.9x | |
$378M | 19.0x | -1281.3x | |
$369M | n/a | -3.0x | |
$365M | n/a | -3.2x | |
$353M | 80.1x | n/a | |
$347M | 6.1x | 23.9x | |
$337M | 1.9x | 8.3x | |
$336M | 9.2x | -2.8x | |
$329M | 13.4x | -6.1x | |
$329M | 3.9x | -7.9x | |
$328M | 4.9x | 32.9x | |
$328M | 0.8x | 7.2x | |
$327M | 2.3x | -1.9x | |
$327M | 1.3x | -1.0x | |
$313M | n/a | -41.6x | |
$304M | n/a | -2.8x | |
$300M | 2.7x | -4.0x | |
$294M | 6.8x | 29.3x | |
$294M | 15.5x | 25.2x | |
$288M | n/a | n/a | |
$280M | n/a | n/a | |
$277M | 4.5x | 10.0x | |
$263M | n/a | n/a | |
$256M | n/a | n/a | |
$255M | n/a | -2.7x | |
$251M | 5.3x | 19.3x | |
$246M | 4.3x | -3.5x | |
$240M | n/a | n/a | |
$236M | 6.0x | -22.0x | |
$232M | 43.1x | -6.1x | |
$223M | 12.6x | -9.6x | |
$221M | 3.0x | -6.5x | |
$216M | 9.3x | -5.5x | |
$215M | n/a | -1.7x | |
$210M | 1.1x | -1.9x | |
$209M | 23.2x | -1.5x | |
$207M | n/a | n/a | |
$204M | 3.1x | n/a | |
$198M | 1.5x | -1.1x | |
$196M | n/a | n/a | |
$194M | n/a | -1.2x | |
$193M | n/a | n/a | |
$186M | 47.6x | -0.8x | |
$184M | n/a | -12.1x | |
$182M | 2.2x | 12.9x | |
$182M | 2.1x | -7.5x | |
$181M | 25.3x | -5.7x | |
$176M | 1.4x | 13.3x | |
$176M | n/a | n/a | |
$170M | n/a | n/a | |
$167M | 4.9x | n/a | |
$166M | 42.5x | -5.8x | |
$162M | n/a | n/a | |
$160M | 13344.5x | -1.6x | |
$158M | 20.8x | -4.4x | |
$153M | 67253.7x | -10.1x | |
$141M | n/a | n/a | |
$140M | n/a | n/a | |
$140M | 5.0x | -4.8x | |
$138M | 11.5x | -3.0x | |
$137M | n/a | n/a | |
$128M | n/a | n/a | |
$128M | 27.0x | -3.2x | |
$127M | n/a | -1.3x | |
$118M | 11.6x | -5.2x | |
$114M | 2.0x | 55.8x | |
$114M | 5.8x | 21.8x | |
$112M | 34.0x | -1.7x | |
$111M | 1.8x | 10.7x | |
$108M | 3.8x | -1.3x | |
$107M | n/a | n/a | |
$103M | n/a | n/a | |
$95.5M | 1.6x | n/a | |
$92.9M | n/a | -6.5x | |
$92.5M | 16.8x | -7.8x | |
$90.5M | 22.2x | -0.7x | |
$90.2M | n/a | n/a | |
$89.5M | 12.0x | -3.0x | |
$83.5M | 2.6x | 11.1x | |
$82.5M | n/a | n/a | |
$82.1M | 2.4x | 9.6x | |
$81.9M | 1.4x | n/a | |
$77.3M | n/a | -12.3x | |
$75.0M | n/a | n/a | |
$73.9M | n/a | n/a | |
$72.0M | 11.3x | 9.5x | |
$71.8M | n/a | n/a | |
$67.0M | n/a | n/a | |
$65.9M | n/a | n/a | |
$63.8M | n/a | n/a | |
$63.6M | n/a | n/a | |
$63.0M | 5.3x | 18.8x | |
$55.4M | n/a | n/a | |
$55.0M | 11.6x | n/a | |
$54.2M | n/a | n/a | |
$53.5M | 9.1x | -39.0x | |
$52.8M | n/a | n/a | |
$48.4M | 743.5x | n/a | |
$46.4M | 8.0x | -5.4x | |
$45.8M | 122.3x | n/a | |
$43.3M | 6.8x | n/a | |
$43.1M | 39.6x | -4.6x | |
$43.0M | n/a | -1.0x | |
$41.3M | n/a | -1.9x | |
$40.2M | n/a | -10.9x | |
$37.4M | 2.2x | -0.2x | |
$37.1M | 71.4x | -3.0x | |
$36.6M | 78.2x | -4.0x | |
$36.1M | n/a | -2.9x | |
$35.9M | n/a | n/a | |
$35.6M | 3.4x | -8.0x | |
$34.0M | n/a | n/a | |
$33.8M | n/a | n/a | |
$33.6M | n/a | -0.2x | |
$33.5M | n/a | n/a | |
$33.1M | n/a | -5.7x | |
$32.9M | 7.8x | n/a | |
$32.5M | 1.3x | 8.5x | |
$32.4M | n/a | n/a | |
$32.3M | n/a | n/a | |
$30.8M | 18.1x | -55.0x | |
$29.3M | 19.1x | -41.6x | |
$28.7M | n/a | n/a | |
$28.3M | n/a | n/a | |
$28.1M | 0.5x | -0.1x | |
$28.0M | n/a | -17.3x | |
$27.6M | n/a | n/a | |
$27.3M | 0.1x | -0.4x | |
$27.2M | n/a | n/a | |
$25.9M | n/a | -15.6x | |
$25.0M | 56.9x | -6.1x | |
$24.3M | n/a | n/a | |
$23.5M | n/a | n/a | |
$23.3M | n/a | n/a | |
$23.2M | n/a | n/a | |
$22.1M | n/a | n/a | |
$21.7M | n/a | -0.1x | |
$21.6M | n/a | n/a | |
$20.7M | n/a | n/a | |
$20.2M | n/a | -14.6x | |
$18.5M | 9.8x | -0.1x | |
$18.0M | n/a | n/a | |
$17.8M | 40.7x | -1.8x | |
$17.3M | n/a | n/a | |
$16.6M | n/a | n/a | |
$16.4M | n/a | n/a | |
$16.3M | 7.7x | -1.1x | |
$15.8M | n/a | n/a | |
$15.8M | 9.3x | n/a | |
$15.6M | 2.5x | 7.8x | |
$15.5M | 2.6x | -2.1x | |
$15.2M | n/a | n/a | |
$14.9M | n/a | n/a | |
$14.8M | 1.7x | -1.0x | |
$14.7M | n/a | -4.2x | |
$14.5M | n/a | n/a | |
$14.3M | n/a | n/a | |
$14.0M | n/a | n/a | |
$13.8M | 2.1x | -10.7x | |
$13.6M | 1.1x | -0.0x | |
$13.5M | 13.0x | -5.6x | |
$13.3M | 12.6x | -1.7x | |
$12.9M | n/a | n/a | |
$12.0M | n/a | n/a | |
$12.0M | n/a | n/a | |
$11.6M | 3.3x | -3.7x | |
$11.5M | n/a | n/a | |
$11.5M | 8.8x | -2.8x | |
$11.1M | 5.7x | -0.7x | |
$11.0M | 150.9x | -7.7x | |
$10.2M | n/a | n/a | |
$9.8M | n/a | -4.9x | |
$9.5M | 7.7x | -17.1x | |
$8.6M | n/a | n/a | |
$8.5M | n/a | n/a | |
$8.4M | n/a | n/a | |
$7.7M | n/a | -3.0x | |
$7.5M | 35.8x | -2.3x | |
$7.3M | n/a | -3.7x | |
$7.2M | 23.0x | n/a | |
$7.0M | 20.5x | -1.9x | |
$6.9M | n/a | n/a | |
$6.9M | n/a | -7.6x | |
$6.7M | n/a | -1.4x | |
$6.1M | n/a | n/a | |
$5.9M | n/a | n/a | |
$5.9M | n/a | n/a | |
$5.9M | n/a | n/a | |
$5.7M | 11.5x | n/a | |
$5.7M | n/a | -1.6x | |
$5.5M | n/a | n/a | |
$4.9M | n/a | n/a | |
$4.2M | 0.6x | -2.7x | |
$4.1M | n/a | n/a | |
$4.0M | n/a | n/a | |
$3.6M | n/a | n/a | |
$3.6M | n/a | n/a | |
$2.9M | n/a | n/a | |
$2.6M | n/a | n/a | |
$2.5M | 6.3x | -0.8x | |
$2.2M | n/a | n/a | |
$2.0M | n/a | n/a | |
$1.9M | n/a | n/a | |
$1.7M | n/a | 2.8x | |
$1.6M | n/a | n/a | |
$1.2M | n/a | n/a | |
$1.2M | n/a | n/a | |
$1.2M | n/a | n/a | |
$1.0M | 1.3x | -0.1x | |
$0.8M | n/a | n/a | |
$0.7M | n/a | n/a | |
$0.6M | 0.7x | n/a | |
$0.5M | n/a | n/a | |
$0.5M | 0.0x | -0.0x | |
$0.5M | n/a | n/a | |
$0.1M | n/a | n/a | |
-$9K | n/a | n/a | |
-$0.8M | n/a | n/a | |
-$1.0M | -0.4x | 0.0x | |
-$1.1M | n/a | n/a | |
-$1.9M | -107.5x | 0.2x | |
-$2.1M | -0.9x | 0.0x | |
-$4.5M | n/a | n/a | |
-$6.2M | n/a | n/a | |
-$6.3M | n/a | n/a | |
-$14.5M | n/a | n/a | |
-$17.8M | -5.3x | 0.4x | |
-$24.1M | n/a | n/a | |
-$25.9M | -0.6x | 0.2x | |
-$26.2M | -5.1x | n/a | |
-$103M | -70.2x | 0.5x | |
-$116M | -34.5x | 1.4x | |
-$1.4B | -4.1x | 7.6x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Biopharmaceuticals